Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Saturday, August 24, 2024
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Obesity medicine euphoria warning: Experts tackle ‘miracle drugs’

October 14, 2023
in News
Reading Time: 4 mins read
A A
Obesity medicine euphoria warning: Experts tackle ‘miracle drugs’
0
SHARES
ShareShareShareShareShare

READ ALSO

Meta says WhatsApp accounts tied to Iran hackers targeted Biden, Trump

Intel has hired Morgan Stanley to defend against activists: sources

Obesity medicine euphoria warning: Experts tackle ‘miracle drugs’

Two experts see major challenges facing the adoption of new obesity drugs.

Dr. Kavita Patel, a physician and NBC News medical contributor, believes fresh data from Novo Nordisk on Ozempic’s ability to delay the progression of chronic kidney disease is among the strongest supporting evidence for secondary uses of the drug.

However, she considers data supporting the use of obesity drugs for other conditions including Alzheimer’s and alcohol addiction as underdeveloped.

“Those trials … are nowhere near as robust as the data we have on [Novo Nordisk trial] FLOW, on sleep apnea, cardiovascular risks, on diabetes control — double-blind placebo, randomized controlled trials that are incredible,” she told CNBC’s “Fast Money” on Wednesday. “We have a long way to go for that. I’ve seen a lot of miracle drugs before.”

Novo Nordisk halted FLOW on Tuesday. According to the company’s press release, it happened more than a year after an interim analysis showed that Ozempic could treat chronic kidney disease in Type 2 diabetic patients.

As of Friday’s close, Novo Nordisk is up 9.82% since its announcement. Its obesity drug maker competitor Eli Lilly is up 5.16% in the same period.

Patel believes efficacy is just one of the major hurdles the medication needs to clear before it can be approved for uses outside of diabetes management.

“We know this drug works really well in diabetics. But there are so many barriers to getting there —including cost, adherence, prescriber rate,” said Patel, who also served as a White House Health Policy Director under President Obama.

Patients opting to use GLP-1 drugs — a group of medications initially designed to control diabetes — for weight management often must pay out-of-pocket.

“Right now, we are seeing active employers, entire states that are declining to cover on the weight loss indication,” Patel said.

What other industries could weight loss drugs disrupt?

If the U.S. Food and Drug Administration approves Ozempic for use in Type 2 diabetics with chronic kidney disease, which Patel believes will happen, it could force the hand of insurance companies to expand their coverage of the drug.

“We’ll see a final package of data that will just be so compelling, that it would be wrong not to cover this, because it should be superior to what we have available to us,” she noted. “That is something that I think the insurance companies will have a difficult time [with].”

Mizuho Health Care Sector Strategist Jared Holz also expects challenges related to insurance coverage as more patients begin taking GLP-1 drugs, which could limit overall adoption.

“The payers, at some point, are going to be saying, ‘We get it, but we cannot pay for these at this volume without seeing the benefit, which may be 10 years from now, 20 years from now, 30.’ We have no idea when the offset is going to be,” he also told CNBC’s “Fast Money.”

Holz also pointed out the divide emerging in the health care sector between Novo Nordisk, Eli Lilly and their pharmaceutical peers.

“We haven’t seen this kind of valuation disconnect between the peer group, maybe in the history of the sector,” he said.

The growth trend may not be sustainable for Novo Nordisk and Eli Lilly, based on current supply constraints that have left patients unable to secure dosages.

“The companies can’t make enough, I don’t think, to actually put out revenue that’s going to appease investors, given where the stocks are trading,” said Holz.

A Novo Nordisk spokesperson did not offer a comment due to the company’s quiet period ahead of earnings. Eli Lilly did not immediately respond to a request for comment.

Credit: Source link

ShareTweetSendSharePin
Previous Post

Why the Trader Joe’s lawsuit against a similarly named crypto firm may not be ‘a slam dunk’

Next Post

Rangers vs. Blue Jackets prediction: NHL odds, pick Saturday

Related Posts

Meta says WhatsApp accounts tied to Iran hackers targeted Biden, Trump
News

Meta says WhatsApp accounts tied to Iran hackers targeted Biden, Trump

August 24, 2024
Intel has hired Morgan Stanley to defend against activists: sources
News

Intel has hired Morgan Stanley to defend against activists: sources

August 24, 2024
Workday stock gains as software provider widens 2027 margin target
News

Workday stock gains as software provider widens 2027 margin target

August 24, 2024
‘More restrictive policy’ may still be needed
News

‘More restrictive policy’ may still be needed

August 23, 2024
Trump DJT stock could be sold within weeks
News

Trump DJT stock could be sold within weeks

August 23, 2024
Nestle CEO replacement not such a bad thing for investors: Analyst
News

Nestle CEO replacement not such a bad thing for investors: Analyst

August 23, 2024
Next Post
Rangers vs. Blue Jackets prediction: NHL odds, pick Saturday

Rangers vs. Blue Jackets prediction: NHL odds, pick Saturday

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

This Anker 3-in-1 MagSafe charging station is cheaper than ever right now

This Anker 3-in-1 MagSafe charging station is cheaper than ever right now

August 12, 2024
What we’re expecting at Google’s 2024 Pixel event

What we’re expecting at Google’s 2024 Pixel event

August 2, 2024
Hamas’ new political leader Yahya Sinwar seen as more extreme

Hamas’ new political leader Yahya Sinwar seen as more extreme

August 7, 2024
MAS sets up review group in bid to revive its SGX development

MAS sets up review group in bid to revive its SGX development

August 2, 2024
Threads introduces a new analytics platform and the option for multiple drafts

Threads introduces a new analytics platform and the option for multiple drafts

August 15, 2024
Simone Biles returns to the Olympics with therapy under her belt

Simone Biles returns to the Olympics with therapy under her belt

July 30, 2024
Susan Wojcicki was the most level-headed of her sisters, mother said earlier

Susan Wojcicki was the most level-headed of her sisters, mother said earlier

August 10, 2024

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Mets take brutal loss to Padres as Paul Blackburn exits with injury
  • The ‘Viking Code’ leadership of Nicolai Tangen, a wealth fund CEO unafraid to lock horns with Elon Musk
  • Carlos Rodon throws latest Yankees gem in blanking of Rockies
  • Meta blocked an Iranian hacking network posing as tech support from Microsoft and Google

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In